TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20207878

Group type: EXPERIMENTAL
Intervention: Mass azithromycin distributions (four biannual treatments)
Number of subjects: 24
Study: 17050036

Group type: EXPERIMENTAL
Intervention: Gum chewing 2 h after lunch
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Gum chewing when hungry
Number of subjects: 47

Group type: COMPARATOR
Intervention: No gum chewing
Number of subjects: 47
Study: 15977870

Group type: EXPERIMENTAL
Intervention: Cyclopentolate 1% + phenylephrine 2.5%
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Tropicamide 1% + phenylephrine 2.5%
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cyclopentolate 0.2% + phenylephrine 1%
Number of subjects: 39
Study: 12077934

Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 69

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 69
Study: 7839779

Group type: EXPERIMENTAL
Intervention: Propofol-nitrous oxide-fentanyl
Number of subjects: 41

Group type: COMPARATOR
Intervention: Thiopentone-isoflurane-nitrous oxide-fentanyl
Number of subjects: 41
Study: 3192871

Group type: EXPERIMENTAL
Intervention: Phazet
Number of subjects: 130

Group type: COMPARATOR
Intervention: SPTs with standardized extracts
Number of subjects: 130
Study: 30785702

Group type: EXPERIMENTAL
Intervention: Smartphone-based Ureteral Stent Tracker (UST) application
Number of subjects: 90

Group type: COMPARATOR
Intervention: Appointment card system
Number of subjects: 90
Study: 28463759

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic surgery (RALS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Laparotomy (LT)
Number of subjects: 120
Study: 26286141

Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol (UMEC/VI) 62.5/25 mcg once daily
Number of subjects: 717

Group type: COMPARATOR
Intervention: Fluticasone propionate/salmeterol (FP/SAL) 500/50 mcg twice daily
Number of subjects: 717
Study: 23946220

Group type: EXPERIMENTAL
Intervention: Low-dose valacyclovir (500 mg twice daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-dose valacyclovir (1 g twice daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21124260

Group type: EXPERIMENTAL
Intervention: Surgical treatment for predominant leg pain in DS patients
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Surgical treatment for predominant leg pain in SpS patients
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Surgical treatment for equal pain groups in DS and SpS patients
Number of subjects: 1206

Group type: COMPARATOR
Intervention: Nonoperative treatment for predominant LBP patients
Number of subjects: 1206
Study: 19840652

Group type: EXPERIMENTAL
Intervention: ProTaper Universal rotary retreatment system
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ProTaper Universal rotary retreatment system with chloroform
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gates‐Glidden and K‐files
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gates‐Glidden and K‐files with chloroform
Number of subjects: 40
Study: 16874005

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 100
Study: 15257469

Group type: EXPERIMENTAL
Intervention: 200 micro g of budesonide
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 800 micro g of budesonide
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 24
Study: 11397610

Group type: EXPERIMENTAL
Intervention: Sympathetic suppressors (n = 12)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Guanethidine (n = 6)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intravenous regional sympathetic blocks (n = 9)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Calcitonin (n = 5)
Number of subjects: 21
Study: 9407327

Group type: EXPERIMENTAL
Intervention: PUFA-enriched soft oil capsules administered after each meal daily for 4 weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: PUFA-enriched soft oil capsules
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control subjects (healthy subjects without liver disease and gastritis)
Number of subjects: 21
Study: 8516523

Group type: EXPERIMENTAL
Intervention: Fentanyl (4 micrograms/kg) and saline (2 ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg) and fentanyl (4 micrograms/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (saline 0.9%)
Number of subjects: 60
Study: 3044238

Group type: EXPERIMENTAL
Intervention: General Anaesthesia (GA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidural Anaesthesia (EA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spinal Anaesthesia (SA)
Number of subjects: 0
Study: 31702673

Group type: EXPERIMENTAL
Intervention: HT048 (1000 mg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: HT077 (400 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 25137146

Group type: EXPERIMENTAL
Intervention: Endotracheal tube cuff pressure maintained at 15 mm Hg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group with cuff pressure monitored without manipulation
Number of subjects: 50
Study: 23348809

Group type: EXPERIMENTAL
Intervention: DTPa-IPV/Hib-MenC-TT (6-in-1 group)
Number of subjects: 142

Group type: COMPARATOR
Intervention: DTPa-IPV-Hib (control group)
Number of subjects: 142
Study: 22103814

Group type: EXPERIMENTAL
Intervention: YKL-40 genotype (TT homozygotes)
Number of subjects: 456

Group type: COMPARATOR
Intervention: Peginterferon/ribavirin therapy
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: YKL-40 promoter polymorphism
Number of subjects: 456
Study: 19267695

Group type: EXPERIMENTAL
Intervention: Threshold ECT (stimulus intensity just above seizure threshold)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Suprathreshold ECT (stimulus intensity 2.5 times seizure threshold)
Number of subjects: 50
Study: 17565166

Group type: EXPERIMENTAL
Intervention: Senior Odyssey program
Number of subjects: 0
Study: 15208277

Group type: EXPERIMENTAL
Intervention: Provision of reproductive health services by GPs
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Urban location of GP clinic
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Female GP
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Postgraduate training in reproductive health
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Knowledge of reproductive health
Number of subjects: 198
Study: 11887809

Group type: EXPERIMENTAL
Intervention: 2-L exchange
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2.5-L exchange
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3-L exchange
Number of subjects: 12

Group type: COMPARATOR
Intervention: 2-L exchange (overnight)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2-L, 2.5-L, and 3-L exchanges
Number of subjects: 12
Study: 9777901

Group type: EXPERIMENTAL
Intervention: Exercise intervention (individual instruction three times per week for 10 weeks)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Usual care (no specific exercise, wait-listed for intervention)
Number of subjects: 51
Study: 7873457

Group type: EXPERIMENTAL
Intervention: formestane (Lentaron) 250 mg every 2 weeks by intramuscular injection
Number of subjects: 409

Group type: COMPARATOR
Intervention: tamoxifen 30 mg/day orally
Number of subjects: 409
Study: 3066848

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 8
Study: 29794959

Group type: EXPERIMENTAL
Intervention: Rapid Cardiopulmonary Assessment (RCPA) performed by senior pediatric residents
Number of subjects: 71
Study: 30257919

Group type: EXPERIMENTAL
Intervention: Graduates from top 10 medical schools (USNWR primary care rankings)
Number of subjects: 996212

Group type: COMPARATOR
Intervention: Graduates from schools ranked ≥50 (USNWR primary care rankings)
Number of subjects: 996212

Group type: EXPERIMENTAL
Intervention: Graduates from higher ranked medical schools (USNWR research rankings)
Number of subjects: 996212

Group type: COMPARATOR
Intervention: Graduates from lower ranked medical schools (USNWR research rankings)
Number of subjects: 996212
Study: 28855800

Group type: EXPERIMENTAL
Intervention: ESS group (n = 409)
Number of subjects: 1152

Group type: COMPARATOR
Intervention: Control group (n = 326)
Number of subjects: 1152
Study: 26296555

Group type: EXPERIMENTAL
Intervention: Pediatric primary care practice‐based smoking prevention and cessation intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 23255208

Group type: EXPERIMENTAL
Intervention: Carotenoid-supplemented formula (L1 and L2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control formula (CTRL)
Number of subjects: 0
Study: 22204063

Group type: EXPERIMENTAL
Intervention: Meloxicam (0.1 mg/kg i.m.)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (0.9% saline i.m.)
Number of subjects: 18
Study: 18502208

Group type: EXPERIMENTAL
Intervention: 0.625 mg/d of conjugated equine estrogens
Number of subjects: 27747

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (0.625 mg conjugated equine estrogens/d plus 2.5 mg medroxyprogesterone acetate/d)
Number of subjects: 27747

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27747

Group type: EXPERIMENTAL
Intervention: Weight loss at 1 year
Number of subjects: 27747

Group type: EXPERIMENTAL
Intervention: Weight gain at 1 year
Number of subjects: 27747

Group type: EXPERIMENTAL
Intervention: Baseline obesity (waist circumference >or=114 cm)
Number of subjects: 27747
Study: 16979494

Group type: EXPERIMENTAL
Intervention: Experimental antiplaque fluoridated formulation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Fluoridated dentifrice
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Resin‐modified glass ionomer cement
Number of subjects: 14

Group type: COMPARATOR
Intervention: Composite resin
Number of subjects: 14
Study: 14609886

Group type: EXPERIMENTAL
Intervention: Sibutramine hydrochloride, 15 mg/d
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 11206010

Group type: EXPERIMENTAL
Intervention: High-dose continuous tamoxifen (200 mg day(-1)), carboplatin (300 mg m(-2) for 3 cycles), and radiotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (historical control with surgery and radiotherapy only)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined therapy (tamoxifen, carboplatin, and radiotherapy)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 50
Study: 8820074

Group type: EXPERIMENTAL
Intervention: Overt rehearsal procedure on a self‐paced, multitrial, free recall task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison boys
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Boys with ADHD
Number of subjects: 0
Study: 1445483

Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptive (30 micrograms ethinyl estradiol + 150 micrograms desogestrel)
Number of subjects: 43
Study: 3904389

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30375179

Group type: EXPERIMENTAL
Intervention: 0.20% CHX + ADS
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 0.20% CHX
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 0.12% CHX + CPC
Number of subjects: 64
Study: 29377866

Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone 0.1 mg/kg (maximum 4 mg) with ropivacaine 0.5% (group D)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Intramuscular dexamethasone 0.1 mg/kg (maximum 4 mg) with ropivacaine 0.5% (group M)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Ropivacaine 0.5% and intramuscular saline (group R)
Number of subjects: 77
Study: 26759167

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT) with Treatment as Usual (TAU)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 60
Study: 24626147

Group type: EXPERIMENTAL
Intervention: Systematic assessment of asthma-like symptoms and ETS exposure using a brief assessment form at intervention centres
Number of subjects: 7775

Group type: COMPARATOR
Intervention: Usual care at control centres
Number of subjects: 7775
Study: 22007690

Group type: EXPERIMENTAL
Intervention: Varenicline 1.0 mg twice daily for 12 weeks with dose titration in the first week
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Varenicline 1.0 mg twice daily for 12 weeks
Number of subjects: 36
Study: 20214496

Group type: EXPERIMENTAL
Intervention: Lupin kernel flour-enriched bread
Number of subjects: 88

Group type: COMPARATOR
Intervention: White bread (control)
Number of subjects: 88
Study: 17693333

Group type: EXPERIMENTAL
Intervention: Traditional Bone Setting (TBS)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Conventional Physiotherapy (PT)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Massage (M)
Number of subjects: 105
Study: 15100671

Group type: EXPERIMENTAL
Intervention: Levocetirizine (5 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Desloratadine (5 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 11464257

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 32 mg once daily
Number of subjects: 611

Group type: COMPARATOR
Intervention: Losartan 100 mg once daily
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 611

Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 611
Study: 9681128

Group type: EXPERIMENTAL
Intervention: Lenograstim (Granocyte) therapy
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no Lenograstim)
Number of subjects: 17
Study: 8004326

Group type: EXPERIMENTAL
Intervention: Small-bore (8F) nasogastric tube
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Large-bore (14F) nasogastric tube
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (no nasogastric tube)
Number of subjects: 11
Study: 2676041

Group type: EXPERIMENTAL
Intervention: Testosterone plus sexual counselling
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo plus sexual counselling
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Testosterone alone
Number of subjects: 30
Study: 970597

Group type: EXPERIMENTAL
Intervention: 1 mg atropine i.v. in normothermia
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 1 mg atropine i.v. in hypothermia
Number of subjects: 25
Study: 30642386

Group type: EXPERIMENTAL
Intervention: High dose AmBisome therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28167194

Group type: EXPERIMENTAL
Intervention: Pilates training using the Reformer machine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 26063890

Group type: EXPERIMENTAL
Intervention: LET (2.5 mg/daily)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: LET-CYC (LET plus oral cyclophosphamide 50mg/daily)
Number of subjects: 107
Study: 23583001

Group type: EXPERIMENTAL
Intervention: Individual reminiscence sessions based on the SolCos model, 6-8 sessions (average 7.4) over 4 weeks
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group with no planned reminiscence treatment
Number of subjects: 82
Study: 21558577

Group type: COMPARATOR
Intervention: 6 mg/kg caffeine (6CAF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 2 mg/kg caffeine (2CAF)
Number of subjects: 12
Study: 19705680

Group type: EXPERIMENTAL
Intervention: Free plus guide mapping
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 82
Study: 16035095

Group type: EXPERIMENTAL
Intervention: rFVIIa 60 or 120 microg/kg
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 12400822

Group type: EXPERIMENTAL
Intervention: Active coronary perfusion (ACP)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Passive coronary perfusion (PCP)
Number of subjects: 151

Group type: COMPARATOR
Intervention: No coronary perfusion (NCP)
Number of subjects: 151
Study: 10787647

Group type: EXPERIMENTAL
Intervention: Permethrin‐impregnated curtains
Number of subjects: 0
Study: 7805231

Group type: EXPERIMENTAL
Intervention: Smoking (current smokers)
Number of subjects: 1619

Group type: COMPARATOR
Intervention: Non-smoking (nonsmokers)
Number of subjects: 1619
Study: 2135223

Group type: EXPERIMENTAL
Intervention: Telenzepine (5 mg, single oral dose)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Salbutamol (2 puffs)
Number of subjects: 18
Study: 389336

Group type: EXPERIMENTAL
Intervention: Hexabrix (32% iodine) - sodium and meglumine salts of ioxaglic acid
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conray 280 (28% iodine) - meglumine iothalamate
Number of subjects: 33
Study: 31382292

Group type: EXPERIMENTAL
Intervention: Patient-reported swollen joints (SJ)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patient-reported tender joints (TJ)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clinically examined swollen joints (SJ)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clinically examined tender joints (TJ)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clinical examination and US findings
Number of subjects: 80
Study: 30844672

Group type: EXPERIMENTAL
Intervention: Self-affirmation intervention prior to informing about chemotherapy-related cognitive problems
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Information about chemotherapy-related cognitive problems
Number of subjects: 90

Group type: COMPARATOR
Intervention: No-information control
Number of subjects: 90
Study: 27285541

Group type: EXPERIMENTAL
Intervention: Microsurgical resection of cerebral AVMs
Number of subjects: 288
Study: 25816807

Group type: EXPERIMENTAL
Intervention: everolimus (trough concentration 3‐8 ng/mL or 6‐12 ng/mL) with reduced cyclosporine
Number of subjects: 833

Group type: COMPARATOR
Intervention: mycophenolic acid (MPA) with standard cyclosporine
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: everolimus (trough concentration 3‐8 ng/mL or 6‐12 ng/mL)
Number of subjects: 833
Study: 23389072

Group type: EXPERIMENTAL
Intervention: TEP
Number of subjects: 314

Group type: COMPARATOR
Intervention: TAPP
Number of subjects: 314
Study: 21411700

Group type: EXPERIMENTAL
Intervention: Aquamantys 6.0 bipolar sealer
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard Bovie electrocautery
Number of subjects: 140
Study: 19392811

Group type: EXPERIMENTAL
Intervention: Massed group CBT (daily 4‐h sessions in week 1, two 2‐h sessions in week 2 and one 2‐h session in week 3)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Traditional spaced weekly group CBT (13 consecutive, weekly 2‐h sessions)
Number of subjects: 39
Study: 17217576

Group type: EXPERIMENTAL
Intervention: Sucrose supplements (4 x 250 ml per day, providing 1800 kJ per day)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Sweetener supplements (4 x 250 ml per day, providing 67 kJ per day)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Sucrose supplements
Number of subjects: 133

Group type: COMPARATOR
Intervention: Sweetener supplements
Number of subjects: 133
Study: 15051557

Group type: EXPERIMENTAL
Intervention: Mediolateral episiotomy
Number of subjects: 519

Group type: COMPARATOR
Intervention: Control (intact perineum or spontaneous lacerations)
Number of subjects: 519
Study: 11451134

Group type: EXPERIMENTAL
Intervention: Cementless fixation
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Hybrid fixation
Number of subjects: 67

Group type: COMPARATOR
Intervention: Cementless and Hybrid fixation
Number of subjects: 67
Study: 9669472

Group type: EXPERIMENTAL
Intervention: Nimodipine 90 mg daily for 12 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: No drug (control)
Number of subjects: 100
Study: 7604632

Group type: EXPERIMENTAL
Intervention: Non-closure of visceral peritoneums (n = 91)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Peritoneal suturing (Control group, n = 149)
Number of subjects: 240
Study: 3394823

Group type: EXPERIMENTAL
Intervention: Norepinephrine (40 ng.kg‐1.min‐1 iv)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (glucose)
Number of subjects: 28
Study: 29631559

Group type: EXPERIMENTAL
Intervention: Baseline subsistence difficulties (none, low, high)
Number of subjects: 306
Study: 29216962

Group type: EXPERIMENTAL
Intervention: Miners who worked for three consecutive days
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Lead exposure
Number of subjects: 94
Study: 23549654

Group type: EXPERIMENTAL
Intervention: PriMa program (n=1553 girls)
Number of subjects: 2086

Group type: EXPERIMENTAL
Intervention: Torera program (n=256 boys, 277 girls)
Number of subjects: 2086
Study: 24168756

Group type: EXPERIMENTAL
Intervention: Fluticasone plus salmeterol
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fluticasone
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fluticasone (alone or in combination with salmeterol)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: COMPARATOR
Intervention: Fluticasone alone
Number of subjects: 45
Study: 19800262

Group type: EXPERIMENTAL
Intervention: Oral glucocorticoids
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intra-articular glucocorticoid injections
Number of subjects: 40
Study: 18241753

Group type: EXPERIMENTAL
Intervention: 12-month supervised exercise program (TPAD-IC)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard medical therapy (CPAD-IC)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Age and mass matched controls (CON)
Number of subjects: 21
Study: 16151785

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% (Alphagan)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 12445849

Group type: EXPERIMENTAL
Intervention: Undercorrected group (blurred by approximately +0.75 D)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Fully corrected control group
Number of subjects: 94
Study: 10321912

Group type: EXPERIMENTAL
Intervention: Parallel group (43 specimens)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Perpendicular group (39 specimens)
Number of subjects: 23
Study: 8881869

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide infusion (0.5, 1, 2, 5 pmol.kg‐1.min‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide infusion (5 pmol.kg‐1.min‐1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (0.9% (w/v) saline)
Number of subjects: 10
Study: 2012585

Group type: EXPERIMENTAL
Intervention: Creative novation behaviour therapy (long-term individual therapy, group therapy, bibliotherapy plus short-term individual treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (suitably matched controls)
Number of subjects: 0